IL23A and psoriasis: Targeting the two members of the IL-23/IL-17 axis, both anti-IL-17 and anti-IL-23 treatment have shown beneficial effects in psoriasis and PsA (16–18), while IL-17 inhibitors rather than IL-23 inhibitors are effective in axSpA.